CELYAD SA/ADR (NASDAQ:CYAD) – Research analysts at Piper Jaffray Companies upped their FY2019 earnings estimates for CELYAD SA/ADR in a note issued to investors on Monday, April 1st, Zacks Investment Research reports. Piper Jaffray Companies analyst E. Tenthoff now forecasts that the company will post earnings of ($3.16) per share for the year, up from their prior estimate of ($3.56). Piper Jaffray Companies currently has a “Overweight” rating and a $41.00 price objective on the stock. Piper Jaffray Companies also issued estimates for CELYAD SA/ADR’s FY2020 earnings at ($3.04) EPS.
CYAD has been the topic of a number of other reports. William Blair reiterated a “buy” rating on shares of CELYAD SA/ADR in a research note on Monday, March 18th. HC Wainwright lifted their target price on CELYAD SA/ADR from $46.00 to $52.00 and gave the stock a “buy” rating in a research note on Tuesday, March 19th. Finally, Zacks Investment Research cut CELYAD SA/ADR from a “buy” rating to a “hold” rating in a research note on Tuesday, January 29th. Two investment analysts have rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. CELYAD SA/ADR presently has a consensus rating of “Buy” and a consensus price target of $43.40.
Several hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Millennium Management LLC raised its stake in shares of CELYAD SA/ADR by 69.6% during the 4th quarter. Millennium Management LLC now owns 90,597 shares of the company’s stock worth $1,645,000 after purchasing an additional 37,171 shares during the period. Victory Capital Management Inc. raised its stake in CELYAD SA/ADR by 4.1% in the 4th quarter. Victory Capital Management Inc. now owns 646,351 shares of the company’s stock valued at $11,738,000 after acquiring an additional 25,189 shares during the period. Finally, Wells Fargo & Company MN raised its stake in CELYAD SA/ADR by 1,109.0% in the 3rd quarter. Wells Fargo & Company MN now owns 6,045 shares of the company’s stock valued at $160,000 after acquiring an additional 5,545 shares during the period. Institutional investors own 7.62% of the company’s stock.
CELYAD SA/ADR Company Profile
Celyad SA, a clinical-stage biopharmaceutical company, focuses on the development of CAR-T cell-based therapies. The company utilizes its expertise in cell engineering to target cancer. Its CAR-T cell platform has the potential to treats a range of solid and hematologic tumors. The company's lead drug product candidate, CYAD-01 (CAR-T NKG2D), has been evaluated in a Phase I clinical trial to assess the safety and clinical activity of multiple administrations of autologous CYAD-01 cells in seven refractory cancers, including five solid tumors, such as colorectal, ovarian, bladder, triple-negative breast, and pancreatic cancers; and two hematological tumors comprising acute myeloid leukemia and multiple myeloma.
Read More: What is a Lock-Up Period?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for CELYAD SA/ADR Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CELYAD SA/ADR and related companies with MarketBeat.com's FREE daily email newsletter.